摘要
目的探讨表柔比星(Epirubicin,EPB)膀胱灌注对预防浅表性膀胱癌(Superficial bladder cancer,SBC)术后复发及副反应方面是否优于丝裂霉素(Mitomycin,MMC).方法将106例SBC术后患者随机分为两组,分别用EPB和MMC作膀胱灌注化疗,灌注化疗期间行血常规、肝肾功能检查.定期随访行膀胱镜或B超,评价肿瘤复发时间记录毒副反应.结果 EPB组51例,平均随访17.1个月,术后1年复发率为17.6%(9/51),MMC组55例,平均随访时间16.4个月,术后1年复发率为18.2%例(10/55),两组患者术后1年复发率差别无统计学意义(P>0.05)；EPB组局部副反应发生率为58.8%(30/51),MMC组局部副反应发生率为56.4%(31/55),两组比较差别无统计学意义(P>0.05).结论 EPB膀胱灌注在预防SBC术后复发及副反应方面并不优于与MMC.
Abstract
Objective To compare the effect on recurrence and safety of Epirubicin and Mitomycin(MMC) by bladder instillation after transurethral resection of superficial bladder carcinoma. Methods 106 patients of superficial bladder carcinoma were randomly divided into two groups respectively. During the chemotherapy, blood liver and kidney function tests were tested Regularly. Follow-up cystoscopy for recurrence of tumor was record. Results 9(17.6%) cases of recurrence was observed in Epirubicin group in the first year after operation, with an mean follow up time of 17.1-month. 10(18.2%%) cases of recurrence was observed in MMC group in the first year after operation, with an mean follow up time of 16.4-month. The incidence of localized side effects was 58.8%(30/51) in Epirubicin group. And in MMC group, the incidence of side effects was 56.4%(31/55). No statistics difference between lolized side effects was observed. Conclusion There were no statistical difference for the effect of recurrence and safety between Epirubicin and MMC by bladder instillation after transurethral resection of superficial bladder carcinoma.
NETL
NSTL
维普
万方数据